AZTY reported sales of NOK 40.4 million (18.5) and an EBITDA of NOK 25.8 million (9.0) for the first quarter of 2021.
Highlights from Q1 2021
· ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by 119% (Q1 2020: NOK 18.5 million)
· Coronavirus-related sales are estimated at NOK 16.5 million in Q1 2021 (NOK 3.8 million in Q1 2020)
·...
Highlights for Q3 2020
• Annual group sales exceed 100 MNOK for the first time
• Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million)
• ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million)
• Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million)
• Upsides...
The Turnaround of ArcticZymes is now definitive. For the second quarter we see impressive growth and the company is firing on all cylinders. Opex (cost) going down while earnings as well as profits surge.
ArcticZymes Q2 report
Sales of NOK 44.3 million (16.9) +262%
EBITDA of NOK 27.2 million (-0.5)
Cash-flow for the Q2 was NOK 20.4 million (-6.8)
Cash at...
ArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate
Tromsø, 02 July, 2020: ArcticZymes AS (OSE:AZT), a subsidiary of ArcticZymes Technologies ASA, announces that it has entered into a supply agreement with vaccine specialist ReiThera Srl (Rome, Italy) for the supply of Salt Active Nuclease...
